PharOS

PharOS Ltd. is a Greek-based private pharmaceutical company established in 2002. Initially founded as a pharmaceutical consultancy firm, it transitioned in 2005 to developing its own products, focusing on market niches in oncology and anti-psychotics. The founders, who retain majority control, are Stella Koukaki, Theodore Panagopoulos, and Panagiotis Panagopoulos. Stella Koukaki, a co-founder and the Scientific Affairs Director, has over 25 years of experience in the generics industry, holding a degree in Chemistry and an MSc in Regulatory Affairs. Panagiotis Panagopoulos joined in 2009 and serves as the Research & Development Director, with a PhD in Drug Metabolism and Pharmacokinetics. Theodore Panagopoulos became a partner in 2007, heading the commercial operations with a background in management and finance.

The company operates on a B2B model, specializing in the development, manufacturing, and supply of generic drugs, over-the-counter (OTC) products, and value-added medicines to other pharmaceutical companies worldwide. Its product portfolio covers therapeutic areas such as antivirals, oncology, central nervous system disorders, and cardiometabolic diseases. PharOS generates revenue by providing a broad portfolio of products and intellectual property, aiming to help clients launch products after patent expiry and extend their market lifecycle. The company serves over 470 clients in more than 115 countries and manages over 9,200 marketing authorizations.

Beyond product development and supply, PharOS offers a comprehensive suite of value-added services. These include contract manufacturing, regulatory affairs, chemistry manufacturing and controls (CMC), pharmacovigilance, and business development consulting. Significant milestones include becoming a founding member of EuDRAcon in 2007, establishing PharOS Polska in 2008, and receiving EU GMP accreditation for batch release in 2015. In 2019, Diorama Investments acquired a stake, which was later sold in a strategic transaction to Armira and Viessmann Generations Group, reflecting the company's sustained growth.

Keywords: pharmaceutical development, generic drugs, value-added medicines, B2B pharma, contract development manufacturing organization (CDMO), regulatory affairs services, pharmaceutical consulting, product lifecycle management, marketing authorization, oncology generics, central nervous system drugs, OTC products, pharmaceutical intellectual property, EU GMP certified, European pharmaceuticals, drug formulation, pharmacovigilance services, batch release services, API sourcing, pharmaceutical supply chain